Shire Seeks to Lure Baxalta Into Talks With $30 Billion Bid

Updated on

What Happens When Drug Companies Get Bigger?

Shire Plc made an unsolicited offer to buy one-month-old Baxalta Inc. for about $30 billion in stock to bolster its focus on rare diseases, a move that may fend off larger drugmakers looking at its own assets for a tax break.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.